Top

memo - Magazine of European Medical Oncology

Published in:

Open Access 07-08-2023 | Trastuzumab Deruxtecan | leading article

Emerging molecular drugs for the treatment of gastroesophageal tumors

Author: Aysegül Ilhan-Mutlu

Published in: memo - Magazine of European Medical Oncology | Issue 3/2023

Excerpt

Despite being a “treatment desert” for decades, new drugs and particularly immunotherapy compounds have significantly changed the treatment algorithm of gastroesophageal (GE) tumors in recent years. This positive trend appears to be continuing as more new molecular drugs are in the pipeline. …

Makhlin I, DeMichele A. Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer. Cell Rep. 2022;3(6):100668. https://doi.org/10.1016/j.xcrm.2022.100668.CrossRef

Van Cutsem E, di Bartolomeo M, Smyth E, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. lancet Oncol. 2023;24(7):744–56. https://doi.org/10.1016/S1470-2045(23)00215-2.CrossRefPubMed

Destiny-Gastric-03, Janjigian YY, ASCO. Abstract Nummer: 295. J Clin Oncol. 2022;40(4_suppl):295–295. https://doi.org/10.1200/JCO.2022.40.4_suppl.295.CrossRef

Takahari D. ASCO 2022. J Clin Oncol. 2022;40(16_suppl):TPS4161–TPS4161. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS4161.CrossRef

Türeci Ӧ, Mitnacht-Kraus R, Wöll S, Yamada T, Sahin U. Characterization of zolbetuximab in pancreatic cancer models. OncoImmunology. 2018;8(1):e1523096. https://doi.org/10.1080/2162402X.2018.1523096.CrossRefPubMedPubMedCentral

Sahin U, Türeci Ö, Manikhas G, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32(5):609–19. https://doi.org/10.1016/j.annonc.2021.02.005.CrossRefPubMed

Kohai S, et al. Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+ (CLDN18.2+)/HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study. J Clin Oncol. 2023;41(4_suppl):LBA292–LBA292. https://doi.org/10.1200/JCO.2023.41.4_suppl.LBA292.CrossRef

Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. https://doi.org/10.1016/S0140-6736(10)61121-X. published correction appears in Lancet. 2010 Oct 16;376(9749):1302.CrossRefPubMed

Ooki A, Yamaguchi K. The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration. Gastric Cancer. 2021;24(6):1169–83. https://doi.org/10.1007/s10120-021-01235-z.CrossRefPubMed

10.

Xiang H, Chan AG, Ahene A, Bellovin DI, Deng R, Hsu AW, Jeffry U, Palencia S, Powers J, Zanghi J, Collins H. Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer. mAbs. 2021;13(1):1981202. https://doi.org/10.1080/19420862.2021.1981202.CrossRefPubMedPubMedCentral

11.

Wainberg ZA, et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022; https://doi.org/10.1016/S1470-2045(22)00603-9.CrossRefPubMed

12.

Smyth EC, Chao J, Muro K, Yen P, Yanes RE, Zahlten-Kumeli A, Rha SY. Phase 3 study of bemarituzumab + mFOLFOX6 versus placebo + mFOLFOX6 in previously untreated advanced gastric or gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-101). J Clin Oncol. 2022;40(16_suppl):TPS4164–TPS4164. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS4164.

13.

Wainberg ZA, Van Cutsem E, Moehler MH, Kang Y-K, Yen P, Finger E, Keegan A, Shitara K. Phase 1b/3 study of bemarituzumab + mFOLFOX6 + nivolumab versus mFOLFOX6 + nivolumab in previously untreated advanced gastric and gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-102). J Clin Oncol. 2022;40(16_suppl):TPS4165–TPS4165. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS4165.

Title: Emerging molecular drugs for the treatment of gastroesophageal tumors
Author: Aysegül Ilhan-Mutlu
Publication date: 07-08-2023
Publisher: Springer Vienna
Keyword: Trastuzumab Deruxtecan
Published in: memo - Magazine of European Medical Oncology / Issue 3/2023
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-023-00905-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2023

How the long-term follow-up is organized in young adult survivors of childhood cancer

Next generation drugs in urothelial cancer: adenoviruses in the treatment of BCG-unresponsive nonmuscle invasive bladder cancer

FlASHback—personal highlights regarding myelodysplastic syndrome from the 2022 ASH meeting

New developments in radiation oncology for head and neck cancers

Current systemic treatment options and new developments in palliative first-line treatment of head and neck squamous cell carcinoma

Nasopharyngeal carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer